Imatinib mesylate (IM) is a first-line treatment of chronic phase-chronic myeloid leukemia (CP-CML). The primary objective of this study was to assess the quality of life (QOL) in patients with CP-CML treated with IM. Ninety patients with newly diagnosed CP-CML were assessed for QOL with first-line IM. Patients completed the cancer-specific FACT-BRM questionnaire (functional assessment of cancer therapy-biologic response modifiers) at baseline and at 3 and 6 months. FACT-BRM consists of subscales including physical well-being (PWB), social and family well-being (SFWB), emotional well-being (EWB), functional well-being (FWB), BRM-physical, and BRM-mental. The primary endpoint was the Trial Outcome Index (TOI), created as a measure of physical function and well-being. An increase of ≥5 from baseline was considered to be a clinically significant improvement. The mean TOI score increased from 75.5 at baseline to 85.2 (p<0.0001) at 6 months, representing a healthy QOL. When comparing the individual TOI subscales, there was a mean increase of 16.4 in the daily functioning and well-being score, and a mean decrease of 6.2, 4.9, and 16.1 was noted in fatigue, emotional/cognitive dysfunction, and side-effects scores at 6 months, respectively. Improvement was not affected by age, sex, or Sokal score. With prolonged treatment, IM results in a higher physical well-being, less fatigue and emotional and cognitive dysfunction, and very few side-effects.
Background: Significant morbidity and mortality is caused by untreated hepatitis B virus infection through cirrhosis and hepatocellular carcinoma. The objectives of our study were to determine distribution of hepatitis B infected population by sex and age groups in District D.I.Khan, Pakistan.Materials Methods: This cross-sectional study was done at District Health Office, D.I.Khan, Pakistan from January 30, 2021 to February 15, 2021. Data was collected for period from March 14, 2013 to January 28, 2021 for 2368 hepatitis B infected cases from population at risk consecutively. Sex and age groups were demographic variables. Data type was nominal for sex and ordinal for age groups. Distribution was analyzed by count, percentage and confidence intervals for proportion for population. Hypotheses for distribution were substantiated by chi-square goodness-of-fit test.Results: Out of 2368 hepatitis B infected population, 1670 (70.52%) were men 698(29.48%) women, and 562 (23.73%) were in age group 0-20 years, 1266 (53.46%) in 21-40 years, 462 (19.51%) in 41-60 years 78 (3.30%) in 60 years. Our distribution by sex (p.00001) and age groups (p.00001) were different than expected respectively.Conclusion: In our study, hepatitis B infection was more common in men than women and most common in age group 21-40 years, followed by 0-20 years, 41-60 years and 60 years. Our observed prevalence of hepatitis B infection in men was higher than expected in women it was lower than expected. Our observed prevalence in the four age groups was not similar to expected.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.